News

Eighteen percent of the Alzheimer disease treatment’s study participants are anticipated to be Black/African American and Latinx, according to an announcement from Biogen and Eisai.

The cognitive neurologist at the University of California, San Francisco discussed the complexities in characterizing milder cognitive disorders and the need for more tailored assessments for these patients. [WATCH TIME: 8 minutes]

At 10 minutes post dose, all 3 AZ-009 dose groups showed a clear reduction from baseline in mean MDS-UPDRS part III score that was greater than for placebo.

Results from the cohort study suggest that a third dose was also associated with modestly increased levels of anti-SARS-CoV02 spike receptor-binding immunoglobulin G antibodies in those who had reduced protective humoral immunity before reimmunization.

After adjusting for baseline scores, no significant correlation emerged between the changes on Epworth Sleepiness Scale and the number of hours of CPAP use.

The founding executive director of the Alzheimer’s Drug Discovery Foundation spoke on the data and developments he is looking forward to seeing in 2022. [WATCH TIME: 3 minutes]

The recurrence of ischemic stroke was less common with dual antiplatelet therapy than with monotherapy in those treated within the 15–180-day window, and similarly common in the 8–14-day period.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada, Las Vegas discussed how the momentum gained within the Alzheimer community can springboard success going forward. [WATCH TIME: 4 minutes]

The cognitive neurologist at the University of California, San Francisco discussed recently published data on the presence of cognitive post-acute sequelae of COVID-19 and the need to legitimize these conditions.

The submission to the FDA is supported by interim data from the RAINBOWFISH trial (NCT03779334), as all 5 babies treated with risdiplam maintained the ability to swallow and feed exclusively orally after 12 months.

Investigators developed a weighted logistic regression-based sleep-wake scoring method for actigraphy data, concluding that it aided in assessing sleep in CP.

The director of the Pediatric Headache Program at CHOP spoke on the challenges associated with clinical trials in pediatric migraine, further discussing the biggest advance made amid the COVID-19 pandemic. [WATCH TIME: 6 minutes]

Approximately 300 patients across 30 clinical centers will be included in the 36-week study evaluating the efficacy and safety of sodium oligomannate (GV-971), a medication currently approved for Alzheimer disease in China.

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center detailed the clinical pre- and post-surgery benefits patients with epilepsy get from MR fingerprinting. [WATCH TIME: 3 minutes]

Device-related adverse events were reported in less than 1% of the safety analysis population, which included more than 100,000 patients with migraine who were treated with Nerivio.

The FDA accepted the new drug application for priority review, setting a PDUFA action date of May 12, 2022.

Patients on the study drug demonstrated improvements in several different exploratory cardiac end points, including NT-proBNP and echocardiographic parameters relative to placebo.

The staff epileptologist at Cleveland Clinic’s Epilepsy Center discussed new untapped ways seizure apps could help patients with epilepsy. [WATCH TIME: 2 minutes]

The senior VP of clinical research and deputy chief clinical officer of the neurology business group at Eisai spoke to the recent first enrollment in the Tau NexGen study of the investigational antimicrotubule binding region tau antibody, E2814.

The cognitive neurologist at the University of California San Francisco provided insight on how she’s taken a cognitive neurology approach to the COVID-19 pandemic, and how her background in HIV influenced her recent research. [WATCH TIME: 5 minutes]

Here's what is coming soon to NeurologyLive®.

The clinical hold comes 2 days after an announcement from Denali Therapeutics detailing a partnership with Takeda Pharmaceutical Company to codevelop and cocommercialize the treatment.

The trial will also include another investiartional Eisai agent, the antiamyloid therapy lecanemab, as the background study drug to evaluate the true effect of E2814 has on patients with dominantly inherited Alzheimer disease.

The director of the Pediatric Headache Program at CHOP commented on the need to treat migraine early to avoid secondary effects and decrease the odds of long-term disability. [WATCH TIME: 3 minutes]

In a Health Union survey of more than 400 patients, those with focal seizures were more likely to say they’ve experienced discrimination, isolation, and reduced productivity at work compared with those without.

Years of mounting data has led the National Headache Foundation to release recommendations on how patients and clinicians come to the right decisions on migraine therapy.

Dubbed COVID-DoC, the prospective study is the largest of its kind to date and provides initial data on the prognosis and pathophysiology of the condition in a group of patients at Massachusetts General Hospital.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 21, 2022.

Discussing the need to identify an effective first-line treatment, the director of the Pediatric Headache Program at CHOP further discussed treatment adherence in this patient population. [WATCH TIME: 5 minutes]